Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
NEW YORK, Sept. 23, 2016 -- The Nasdaq Stock Market announced today that it will delist the common stock of BIND Therapeutics, Inc. BIND Therapeutics, Inc.’s stock was suspended on August 01, 2016 and has not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock and warrant of InterCloud Systems, Inc. InterCloud Systems, Inc’s common stock and warrant were suspended on August 31, 2016 and have not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock of Echo Therapeutics, Inc. Echo Therapeutics, Inc.’s stock was suspended on July 12, 2016 and has not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock, warrant, unit and right of 1347 Capital Corp. 1347 Capital Corp.’s common stock, warrant, unit and right were suspended on July 12, 2016 and have not traded on Nasdaq since that time.
Finally, Nasdaq announced that it will delist the common stock of EPIRUS Biopharmaceuticals, Inc. EPIRUS Biopharmaceuticals, Inc.’s stock was suspended on August 04, 2016 and has not traded on Nasdaq since that time.
Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting for each of these companies. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delistings and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: http://www.cchwallstreet.com/NasdaqTools/bookmark.asp?id=nasdaq-rule_5800&manual=/nasdaq/main/nasdaq-equityrules/.
NDAQO
